B&A Acquires Celestar, Expanding Intelligence Capabilities Across Defense and Intelligence Markets

Acquisition Broadens B&A’s Intelligence Capabilities and Strengthens its Position as a Growing National Security Partner   McLean, Va., January 13, 2026 – B&A, a leading information technology systems integrator serving the federal government, today announced it has acquired Celestar Corporation, a global, multi-disciplinary intelligence services and solutions provider. Celestar provides specialized intelligence and analytic support to… Read more »

Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroesophageal Reflux Disease

Key Highlights: Sebela Pharmaceuticals® submitted its New Drug Application (NDA) for tegoprazan on January 9, 2026.  The NDA seeks approval for three indications: Non-Erosive Reflux Disease (NERD), Erosive Esophagitis (EE) Healing, and EE Maintenance Once approved, tegoprazan will be the first Potassium-Competitive Acid Blocker (P-CAB) to demonstrate superiority in EE healing across all severity grades (LA… Read more »